Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation

Dendritic cell (DC)–based immunotherapies are believed to help eradicate residual tumor cells, including hepatocellular carcinoma (HCC). Here, we assessed the safety and clinical response to OK432-stimulated monocyte-derived DCs (MoDCs) in treating HCC after radiofrequency ablation (RFA). MoDCs were...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitahara, Masaaki, Mizukoshi, Eishiro, Terashima, Takeshi, Nakagawa, Hidetoshi, Horii, Rika, Iida, Noriho, Arai, Kuniaki, Yamashita, Taro, Sakai, Yoshio, Yamashita, Tatsuya, Honda, Masao, Nakamoto, Yasunari, Kaneko, Shuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226894/
https://www.ncbi.nlm.nih.gov/pubmed/32413834
http://dx.doi.org/10.1016/j.tranon.2020.100777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226894/
https://www.ncbi.nlm.nih.gov/pubmed/32413834
http://dx.doi.org/10.1016/j.tranon.2020.100777

Ejemplares similares